Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

TOKYO (Kyodo) -- A single course of newly approved Alzheimer's drug donanemab-azbt ... The drug developed by U.S.

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

I’m Diane Brady. From transformative weight loss treatment to a potential blockbuster for Alzheimer's, Dave Ricks of Eli ...

Essence may receive compensation for some links to products and services on this website. Offers may be subject to change ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

Britain’s National Health Service (NHS) has announced that it will not cover Eli Lilly’s new Alzheimer’s drug, donanemab.

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

My father has developed painful bedsores in his nursing home, and I’m convinced it’s due to poor care. What can I do? I've ...